Who are SPD503 (2 mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Barhemsys, Rexulti, Vraylar, Aristada, Lonasen, Neupro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spd503-2-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SPD503 (2 mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SPD503 (2 mg) (SPD503 (2 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: dopamine receptor agonist. Area: Neurology.

phase 3 dopamine receptor agonist Dopamine receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

SPD503 (2 mg) (SPD503 (2 mg)) — Shire. SPD503 is a dopamine receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SPD503 (2 mg) TARGET	SPD503 (2 mg)	Shire	phase 3	dopamine receptor agonist	Dopamine receptor
Barhemsys	AMISULPRIDE	Acacia	marketed	Dopamine-2 Receptor Antagonist [EPC]	D(2) dopamine receptor	2020-01-01
Rexulti	BREXPIPRAZOLE	Otsuka	marketed	Atypical Antipsychotic [EPC]	D(2) dopamine receptor	2015-01-01
Vraylar	CARIPRAZINE	AbbVie	marketed	Atypical Antipsychotic [EPC]	D(3) dopamine receptor	2015-01-01
Aristada	ARIPIPRAZOLE LAUROXIL	Alkermes Inc	marketed		D(2) dopamine receptor	2015-01-01
Lonasen	BLONANSERIN	Dainippon Sumitomo Pharma Co., Ltd.	marketed	blonanserin	D(2) dopamine receptor	2008-01-01
Neupro	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (dopamine receptor agonist class)

Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPD503 (2 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/spd503-2-mg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing